## IAAP VIRTUAL Spring Conference October 23, 2020

# Earn up to 6.0 CEUs at SPECIAL "VIRTUAL" PRICING! With Guest Speaker, Darryl S. Inaba, PharmD. CATC-V, CADC III



Dr. Inaba is Director of Clinical and Behavioral Health Services for the Addictions Recovery Center and Director of Research and Education of CNS Productions in Medford, Oregon. He is an associate Clinical Professor at the University of California in San Francisco, CA., and a Lifetime Fellow at Haight Ashbury Free Clinics, Inc., (Health Right 360) in San Francisco, CA. As Director of Education and Research at CNS Productions, Inc. in Medford, OR, Dr. Inaba has authored several papers, award winning educational films and is co-author of <u>Uppers, Downers, All Arounders</u> a text on addiction and related disorders that is used in more than 400 colleges and universities. He has been honored with over 90 individual awards for his work in the areas of prevention and treatment of substance abuse problems.

#### **SCHEDULE**

9:00 am – 11:00 am Welcome & Introduction

Morning Session

11:00 am – 11:15 am Break

M · C · (

11:15 am – 12:15 pm 12:15 pm -1:15 pm Morning Session (continued) IAAP Annual Membership

I IAAI AII

Meeting & Lunch Break

1:15 pm - 3:15 pm

Afternoon Session

3:15 pm - 3:30 pm

Break

3:30 pm - 4:30 pm

Session Conclusion

Certificates of Attendance will be emailed to all attendees following the conference.

### Marijuana: New Findings, Mental Health Concerns, Cannabis Use Disorder (CUD) – Inconvenient Truths

The Indiana Association for Addiction Professionals

Most states now legalize either medical or recreational use of marijuana despite increasing medical evidence that demonstrate its use, especially in its newer highly potent forms ("dabs, vapes, edibles") and synthetic cannabinoids ("Spice") result in addiction, medical and mental health problems. Increased use especially by youth has resulted in increased reports and studies associating its use to accidents, adverse medical/law enforcement interventions, psychosis, thought disorders, loss of IQ, seizures, syncope, hyperemesis, heart and other medical complications. This presentation will look at marijuana as a drug: Its mental health and abuse

complications as well as its potential benefits in the treatment of some medical disorders. The botany, chemistry, pharmacology, impact on the adolescent brain and especially the 8-9% of users who develop Cannabis Use Disorder (CUD) will be explored. Current treatments of CUD will also be reviewed.

### Opioid Crisis Overview: History, Current Trends, Pharmacology and Developments in Treatments

The National Institute on Drug Abuse estimates the co-morbidity of addiction and chronic pain to vary widely from 3 to 40%. Those working in either addiction treatment or in the management of chronic pain would usually lean towards the higher projection of this co morbid disorder. The 2015 NIH White Paper documents a current epidemic of prescription opioid addiction and opioid overdose deaths. On October 26, 2017, President Trump declared the Opioid Crisis a Public Health Emergency with 6-8 Americans dying every hour of an opioid overdose. This persists through 2020 and has even increased during the COVID pandemic. Iatrogenic opioid addiction once considered to be very rare in now more common. Treatment of especially opiate/opioid use disorder in a patient with chronic pain continues to be a very difficult challenge as is the treatment of pain in patients with any substance-related and addictive disorder. A historical swing between over and under treatment of pain will be considered. Pharmaceutical Industry attempts to produce diversion resistant opioid medications and how these efforts continued to be thwarted by abusers and/or merely promote the abuse of heroin and other illicit opioids will be examined. This presentation will then review the current increase in opioid overdose and addiction problems especially in patients treated for chronic pain. The wide range opioid substances currently abused will also be examined inclusive of Kratom, a nonopioid substance with major opioid effects. Brain imaging of both physical and emotional pain will be examined. Newer understandings of how hyperalgesia, hyperpathia, hyperkatifeia, allodynia, and opioid addiction compromise the use of opioids in the treatment of chronic pain will be explained and treatment developments for Opioid Use Disorder will conclude the presentation.



## **REGISTRATION**

## IAAP VIRTUAL FALL CONFERENCE

OCTOBER 23, 2020 – 9:00 am to 4:30 pm Earn up to 6 CEU's

Name:			
Address:			
City, State, Zip:			
Email:		Phone:	
SPECIAL VIRTUAL FEES	S!		
f paying with Credit Card add fee \$5.00			
<b>Refund Policy:</b> Refunds will be issued, minus a \$15 service charge, if requested on or before 10/16/2020.		Method of PaymentCheck (payable to IAAP) Credit C	ard
		CC #:	
AAP Member AAP Non-Member AAP Student Member	\$100	Exp. Date:CVV:	
		Signature:	
		Billing Zip Code:	

**Total Amount Due** 

Register online at <a href="www.iaapin.org">www.iaapin.org</a>
or

Mail Registration with Payment to:
IAAP
PO Box 68178
Indianapolis, IN 46268-0178

**Questions?** Call IAAP Central Office at 317-481-9255